TAXUS V
This article was originally published in The Gray Sheet
Executive Summary
Preliminary safety data from Boston Scientific's TAXUS V de novo lesion trial indicate its Taxus Express2 paclitaxel-eluting stent met all pre-specified safety targets in the most difficult patients treated in the TAXUS study series to date, the company announces March 31. Trial enrollment now is complete with 1,172 patients (64 more than originally planned). Nine-month follow-up data will be available in early 2005...